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Phasic Dopamine Release Evoked by Abused Substances
Requires Cannabinoid Receptor Activation
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Transient surges of dopamine in the nucleus accumbens are associated with drug seeking. Using a voltammetric sensor with high
temporal and spatial resolution, we demonstrate differences in the temporal profile of dopamine concentration transients caused by
acute doses of nicotine, ethanol, and cocaine in the nucleus accumbens shell of freely moving rats. Despite differential release dynamics,
all drug effects are uniformly inhibited by administration of rimonabant, a cannabinoid receptor (CB1 ) antagonist, suggesting that an
increase in endocannabinoid tone facilitates the effects of commonly abused drugs on subsecond dopamine release. These time-resolved
chemical measurements provide unique insight into the neurobiological effectiveness of rimonabant in treating addictive disorders.
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Introduction
In 2004 alone, 21.1 million Americans were untreated for their
addictions at a profound societal cost (Chou and Narasimhan,
2005). Recent insights into the neurobiology of abused drugs
have advanced the development of potential therapeutic agents
for at-risk individuals (O’Brien and Gardner, 2005). One of
these, rimonabant [N-piperidino-5-(4-chlorophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-pyrazole-3-carboxamide (SR141716A)];
Acomplia], a CB1 receptor antagonist, attenuates many addictive
behaviors (Arnold, 2005; Castane et al., 2005; Cohen et al., 2005;
Colombo et al., 2005; Gardner, 2005). Emerging evidence indi-
cates that the endocannabinoid system can interact with dopa-
mine within the mesolimbic system, providing a candidate mech-
anism for the effects of rimonabant on addiction models
(Hungund et al., 2003; Cheer et al., 2004; Cohen et al., 2005).
For almost two decades, it has been recognized that dopamine
neurotransmission is critical in the reinforcing properties of ad-
dictive substances (Di Chiara and Imperato, 1988). Specifically,
brain microdialysis studies showed that most abused drugs cause
a prolonged increase in extracellular dopamine in the nucleus
accumbens (NA). This finding, now commonly accepted, was
initially surprising because the drugs studied act through very
different pharmacological mechanisms. Recent chemical mea-
surements with higher temporal resolution reveal that cocaine
also induces highly dynamic dopamine concentration fluctua-
tions that are superimposed on the prolonged rise in ambient
levels (Heien et al., 2005). These dopamine fluctuations are
highly important because they have been shown to accompany
reward seeking (Robinson et al., 2002b; Phillips et al., 2003; Roit-
man et al., 2004). Here, we show that other abused drugs also
cause dopamine fluctuations in the NA and that the fluctuations
are characteristic of the individual drugs. More importantly, even
when induced with relatively high doses, we show that these fluc-
tuations can be attenuated by rimonabant, establishing a role for
cannabinoid receptors in the actions of abused drugs.
Materials and Methods
Animals and surgery. The procedures for voltammetric experiments in
freely moving Sprague Dawley rats have been described previously
(Heien et al., 2005). Rats (n  39; 250 –350 g; Charles River, Wilmington,
MA), implanted with a jugular vein catheter, were surgically prepared
48 h before experiments. A guide cannula (BAS, West Lafayette, IN) to
hold the microdrive for the carbon-fiber electrode was cemented in place
above the NA shell (1.7 mm rostral, 0.8 mm lateral relative to bregma),
and a bipolar stimulating electrode (Plastics One, Roanoke, VA) was
permanently affixed in the ventral tegmental area (VTA) (1 mm lateral,
5.2 mm caudal, and 8.2 mm ventral from the surface of the brain). An
Ag/AgCl reference electrode was implanted in the contralateral
hemisphere.
In vivo voltammetry. After recovery from surgery, a fresh cylindrical
(length, 100 m) carbon-fiber microelectrode was lowered into the
NA shell of an awake rat using the microdrive secured into the guide
cannula. Voltammetry used a triangular waveform (0.4 to 1.3 V vs a
Ag/AgCl reference) at 400 V/s, repeated every 100 ms. Electrical stimu-
lations delivered through the bipolar electrode (24 pulses; 2 ms each
phase; 125 A; 60 Hz) were used to evoke dopamine and pH changes in
the NA for use as the training set for principal component analysis (Heien
et al., 2005). To optimize recording of transients, the electrode position
was further adjusted to a location where spontaneous dopamine tran-
sients occurred with a frequency of 1 per minute. Once a recording site
with transients was found, voltammograms were continuously collected.
Naturally occurring dopamine transients were recorded for 15 min, and
this epoch is termed the baseline.
Dosing regimen. To evaluate the ways in which rimonabant modifies
the effects of cocaine, ethanol, and nicotine on dopamine release, two
groups of animals were compared for each abused drug. For cocaine and
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ethanol experiments, a within-subject regimen
was used. First, saline was administered, fol-
lowed 15 min later by the drug under study.
Rimonabant was given 4.5 min later, and 28.5
min thereafter a second dose of the drug was
administered. The control group was identical
except vehicle was administered after the drug
under study. Experiments with nicotine used a
between-subject design. One group received ve-
hicle, whereas the other received rimonabant.
Nicotine was administered 4.5 min later.
Data analysis. After background subtraction,
three-dimensional color plots of the voltam-
metric data were used to examine the responses
as in supplemental Figure 1 (available at www.
jneurosci.org as supplemental material). Dopa-
mine changes were evaluated with principal
component regression (Heien et al., 2005). This
method allows dopamine concentration
changes to be extracted from data at the 95%
confidence level for epochs up to 90 s long.
When evaluated for longer time periods, the re-
sidual becomes larger. However, rapid concen-
tration changes, termed transients herein, can
be extracted from multiple 90 s blocks allowing
transient identification over many minutes.
Mini Analysis (Synaptosoft, Decatur, GA) was
used to determine the frequency, half-width,
and amplitude of the dopamine transients. A
fluctuation in the dopamine traces was deemed
a transient if it was at least three times greater
than the root mean square noise from data
measured at a time when rapid chemical activ-
ity was not occurring. To determine the tran-
sient amplitude, the baseline was taken as the
first minima located 0.3– 0.6 s before the peak.
Both the amplitude and frequency of dopamine transients for each drug
as well as the effects of rimonabant were analyzed using two-way ANOVA
(repeated measures) for within-subject comparisons (cocaine and etha-
nol). Bonferroni’s post hoc tests were used to assess between-subject dif-
ferences when interactions [sample (cocaine/EtOH) and treatment (ve-
hicle/rimonabant)] were significant, whereas Scheffé’s post hoc tests were
used to assess significant differences for within-subject comparisons.
Student’s t tests for independent samples were used for between-subject
(nicotine) comparisons. The criterion for significance was set at p  0.05.
STATISTICA (StatSoft, Tulsa, OK) was used for statistical analyses.
Drugs. Cocaine (3 mg/kg) and nicotine (0.3 mg/kg) (both from Sigma-
Aldrich, St. Louis, MO) were suspended in saline. Ethanol (Aaper Alco-
hol, Shelbyville, KY) was mixed in saline at 0.3 g/ml and was adminis-
tered at 1 g/kg. Rimonabant (SR141716A) (Research Triangle Institute–
National Institute on Drug Abuse, Raleigh, NC) was freshly suspended in
a 1:1:18 ratio of ethanol, emulphor (Alkamuls EL-620; Rhodia, Cran-
bury, NJ), and heparinized saline (0.9%). All drugs were administered
intravenously through an indwelling jugular vein catheter.
Results
Extracellular dopamine after cocaine, nicotine, and ethanol
Freely moving rats were placed in a behavioral chamber and the
carbon-fiber electrode was placed in the NA at a site that exhib-
ited spontaneous dopamine transients occurring at 1 per
minute. After 15 min of baseline collection, they were adminis-
tered 1 ml of saline intravenously. This did not significantly alter
the frequency or amplitude of dopamine transients, nor did it
affect the dopamine steady-state concentration (vide infra). Co-
caine (3 mg/kg), ethanol (1 g/kg), or nicotine (0.3 mg/kg) were
administered intravenously at doses demonstrated previously to
have robust effects either on dopamine extracellular concentra-
tions or behavior (Di Chiara and Imperato, 1988; Budygin et al.,
2001; Robinson et al., 2002a; Heien et al., 2005; Matta et al.,
2006).
As previously shown (Heien et al., 2005), extracellular dopa-
mine concentration, extracted by principal component regres-
sion (supplemental Fig. 1, available at www.jneurosci.org as sup-
plemental material), gradually increased and appeared to plateau
during the 90 s observation time after 3 mg/kg cocaine (n  5)
(example in Fig. 1A, top panel). Superimposed on this gradual
change were dopamine transients that are significantly greater in
frequency (Fig. 1B) than after saline. Ethanol elicited more vari-
able results (n  9). In approximately one-half of the measure-
ment sites, ethanol injection significantly increased transient fre-
quency over control levels (Fig. 2A, top panel; B, C). Nicotine
(0.3 mg/kg; n  4) caused a gradual increase in extracellular
dopamine (Fig. 1A, right panel) that subsequently declined in the
measurement interval. The timescale of this change is similar to
that observed for regional cerebral blood flow in the rat nucleus
accumbens with a similar dose (Gozzi et al., 2006). More frequent
dopamine transients were superimposed on this response (Fig.
3A, top panel; B).
Although all three abused drugs increased the frequency of
dopamine transients, there were quantitative differences. With
the doses used, the frequency of dopamine transients was in-
creased most after cocaine (250% increase from saline) (Fig. 1B)
followed by nicotine (181% increase from saline) (Fig. 3B) and
the ethanol-responsive sites (169% from saline) (Fig. 2B).
Whereas the amplitude of ethanol-evoked dopamine transients
was unaltered, regardless of sampling site (Fig. 2C), the other two
drugs increased transient amplitude compared with saline (260%
Figure 1. Endocannabinoids mediate cocaine-induced increases in subsecond dopamine release. A, Representative traces of
dopamine extracellular concentration fluctuations after an injection of cocaine after saline (top), the attenuation of this response
by rimonabant after a second cocaine administration (middle) in the same animal and recording location, as well as the effects of
saline injection at the same site (bottom). The arrow and dashed line indicate time of drug administration. B, Pooled data of the
frequency of dopamine transients ( fDA) in the 4.5 min after the end of each intravenous drug infusion (animals in the control
group are shown in white bars). S, Saline; C, first dose of cocaine (3 mg/kg); V/Ri, vehicle (n4) or rimonabant (n5; 0.3 mg/kg)
injection 4.5 min after first dose of cocaine; C2, second dose of cocaine (3 mg/kg) given 30 min after vehicle or rimonabant
(Scheffé’s test, *p  0.05 compared with saline; Bonferroni’s test, ^ p  0.05 vehicle vs rimonabant-treated animals; Bonferro-
ni’s test, &p  0.05 vehicle vs rimonabant-treated animals). C, Amplitude of drug-evoked dopamine transients ([DA]max). Error
bars indicate SEM.
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after nicotine and 220% after cocaine)
(Figs. 1C, 3C). Furthermore, the overall
(steady-state and transient) increase in do-
pamine was twofold higher after nicotine
compared with cocaine. The half-width of
dopamine transients was significantly in-
creased after cocaine (from 0.85  0.1 to
1.4  0.2 s; p  0.05), but it was un-
changed after ethanol and nicotine. Addi-
tionally, whereas the cocaine and ethanol
effects lasted beyond the interval shown,
maximal nicotine effects on dopamine
concentration were shorter-lived on aver-
age, probably because of receptor desensi-
tization (Pidoplichko et al., 1997). Consis-
tent with desensitization, no changes in
dopamine release were seen after adminis-
tration of a second dose of nicotine (data
not shown).
Dopamine release induced by cocaine
critically depends on CB1
receptor activation
A within-subjects design was used to test
the effects of CB1 receptor blockade on
subsecond dopamine release changes in-
duced by cocaine (Fig. 1A, middle panel)
obtained in the same animals as above
(sample and treatment interaction, F(3,21) 
3.1; p  0.05). Pooled data show that
rimonabant given 4.5 min after cocaine
significantly reduced the frequency of do-
pamine transients (Fig. 1B). A subsequent
dose of cocaine (3 mg/kg) 30 min after
rimonabant (when the effects of the initial
dose had subsided) did not significantly
raise transient dopamine release above
baseline levels (Fig. 1A, middle panel; B).
Indeed, transient frequency after the sec-
ond dose of cocaine in the presence of
rimonabant was significantly lower than
that induced by cocaine after saline (Fig.
1B) (sample, F(3,21)  11.7, p  0.0001;
16.2  3.2 vs 4.9  2.1 transients per 90 s;
Scheffé’s test, p  0.05). Rimonabant also
reversed the increase in amplitude of do-
pamine transients after the first cocaine
administration (Fig. 1C) and significantly
prevented the rise in amplitude after the
second dose of cocaine (Fig. 1A, middle
panel; C) (sample, F(3,21)  3.3, p  0.05;
77  9 vs 39  5 nM; Scheffé’s test, p 
0.05). No changes in transient frequency
or amplitude were observed after vehicle
injection (n  4) (Fig. 1B,C). Rimonabant
did not alter the effects of cocaine on tran-
sient half-width as predicted by the lack of
effect of the CB1 antagonist on dopamine
uptake (Cheer et al., 2004). We also found
a significant attenuation of cocaine-
induced increases in locomotion by
rimonabant (n  5) (supplemental Fig. 2,
available at www.jneurosci.org as supple-
Figure 2. Cannabinoid receptor blockade attenuates the effects of ethanol of subsecond dopamine release. A, Traces depicting
ethanol-induced extracellular dopamine fluctuations after saline injection (top), the attenuation of this response by rimonabant
after the second ethanol administration (middle) in the same animal and recording location, and the effects of saline injection at
the same site (bottom). The arrow and dashed line indicate time of drug administration. B, Pooled data from ethanol-responsive
sites of the frequency of dopamine transients ( fDA) in the 4.5 min after the end of each intravenous drug infusion (animals in the
control group are shown in white bars). S, Saline; E, first dose of ethanol (1 g/kg); V/Ri, vehicle (n  8) or rimonabant (n  9; 0.3
mg/kg) injection 4.5 min after first dose of ethanol; E2, second dose of ethanol (1 g/kg) given 30 min after vehicle or rimonabant
(Scheffé’s test, *p  0.05 compared with saline). C, Amplitude of drug-evoked dopamine transients ([DA]max). Error bars indicate
SEM.
Figure 3. Nicotine elicits a potent dopamine spillover mediated by CB1 receptors. A, Dopamine trace showing the effects of
nicotine injected after saline on subsecond dopamine release (top) and the dopamine response to nicotine when injected to a
different animal in the presence of rimonabant (middle). The bottom panel shows the effects of vehicle injection (recorded from
the same site as the trace shown in the top panel). The arrow and dashed line indicate time of drug administration. B, Pooled data
of the frequency of dopamine transients ( fDA) in the 4.5 min after the end of each intravenous drug infusion. V/Ri, Vehicle (n 
4) or rimonabant (n  4; 0.3 mg/kg) injection; nicotine injection (0.3 mg/kg) given 4.5 min after vehicle (V-nic) or rimonabant
(Ri-nic). (Student’s t test, *p  0.05 compared with vehicle; &p  0.05, vehicle vs rimonabant-treated animals). C, Amplitude of
drug-evoked dopamine transients ([DA]max). Error bars indicate SEM.
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mental material), demonstrating a parallel functional conse-
quence of disrupting endocannabinoid signaling.
Endocannabinoid receptors control the effects of ethanol on
rapid dopamine release
The effects of rimonabant (0.3 mg/kg) on ethanol-evoked
changes in dopamine were similarly assessed (Fig. 2A, middle
panel) (sample and treatment interaction, F(3,45)  4.8; p  0.05).
In ethanol-responsive sites, rimonabant given 4.5 min after eth-
anol (1 g/kg) significantly reversed the increase in the frequency
of dopamine transients caused by ethanol administration (Fig.
2B) and further prevented the effects of a subsequent dose (1
g/kg) given 30 min later, when the effects of the initial dose had
subsided (Fig. 2A, middle panel; C) (sample, F(3,45)  8.5; p 
0.0001; 14.7  2.2 vs 6.9  1.8 transients per 90 s; Scheffé’s test,
p  0.05). Vehicle injection (n  8) did not modify dopamine
release after ethanol (Fig. 2B,C).
Cannabinoid receptor blockade attenuates the subsecond
dopaminergic response to nicotine
Recent clinical trials (STRATUS-US) have shown that rimon-
abant (20 mg) doubles smoking cessation rates for subjects mo-
tivated to quit compared with placebo (De Vries and Schof-
felmeer, 2005). Thus, we examined the effects of rimonabant on
the acute dopamine-releasing properties of nicotine. A between-
subject design to assess the effects of rimonabant (0.3 mg/kg) on
nicotine-induced subsecond dopamine changes was used to
avoid desensitization confounds. Rimonabant pretreatment pre-
vented the nicotine-induced changes in frequency and amplitude
of individual transients observed in vehicle controls (n  4) and
diminished the rise in area under the steady-state dopamine con-
centration trace (Fig. 3A, middle panel; B, C).
Discussion
This study confirms that pharmacologically distinct drugs of
abuse usurp dopaminergic circuitry (Di Chiara and Imperato,
1988), but in strikingly different ways. Nicotine increases dopa-
mine release as evidenced by increased transient frequency and
amplitude; ethanol increases transient frequency, whereas co-
caine amplifies dopamine transients by inhibiting its uptake. Re-
markably, despite the mechanistic differences of these three
drugs, rimonabant curtails the dopamine responses in each case.
For all three drugs, the effects of rimonabant are attributable to
an endocannabinoid– drug interaction because rimonabant
alone does not affect transient frequency or amplitude in the NA
(Cheer et al., 2004). Of particular interest is the suppression of
drug-induced dopamine transients by rimonabant because these
have been associated with drug seeking (Phillips et al., 2003) as
well as acquisition of natural rewards (Roitman et al., 2004).
Indeed, because the doses of abused drugs used in this study were
quite high, it is remarkable that rimonabant was capable of mod-
ifying their effects on dopamine neurotransmission, both with
respect to the gradual change and the dopamine transients.
The main action of cocaine on dopaminergic neurons is to
inhibit the dopamine transporter. This action is apparent in our
data as an increase in the half-width of the transients caused by an
inhibition of the rate of uptake of released dopamine in the ter-
minal regions. The apparent increased transient frequency after
cocaine may be a direct consequence of this transporter blockade,
which would render small transients more detectable (Heien et
al., 2005). However, cocaine-induced changes in dopamine re-
lease critically depend on dopamine neuron activity (Nomikos et
al., 1990), and several mechanisms have been identified that ex-
plain how psychostimulants may increase the firing and bursting
rates of VTA dopamine neurons under certain conditions (Lu-
pica and Riegel, 2005). Nicotine acts on the dopaminergic system
by increasing burst firing of mesolimbic dopaminergic neurons
(Pidoplichko et al., 1997) and enhances dopamine release
through calcium-dependent mechanisms (Turner, 2004). In our
experiments, this modulation results in larger dopamine tran-
sients before desensitization occurs. Ethanol is known to increase
the firing rate of dopaminergic neurons (Gessa et al., 1985), but
decreases the amplitude of electrically evoked dopamine release
(Budygin et al., 2001) without affecting the rate of dopamine
uptake (Robinson et al., 2005).
Our findings complement many existing reports concerning
dopamine and CB1 receptor interactions. For example, Cohen et
al. (2005) found that nicotine, at a dose similar to that used here,
elevated NA shell dopamine dialysate for at least 200 min, and
this was attenuated by rimonabant pretreatment. Nicotine bind-
ing induces much less desensitization of 7 subunits of nicotinic
acetylcholine receptors (nAChRs) on glutamate terminals
(Cohen et al., 2005) than of 42 nAChRs on GABAergic cells,
resulting in prolonged excitatory input to dopamine cells. The
long-lasting change observed with microdialysis may thus be at-
tributable to 7 nAChR receptor activation, whereas the imme-
diate changes in extracellular dopamine release seen with volta-
mmetry may depend mostly on 42 nAChRs. Subsecond
dopamine neurotransmission is thought to encode associative
aspects of reinforcement (Schultz et al., 1997); therefore, the in-
hibition of nicotine-induced rapid dopamine release by rimon-
abant may underlie its ability to reduce cue-induced nicotine
craving and dependence (Le Foll and Goldberg, 2005). This is
especially important in nicotine abuse because the addition of
cues has been shown to increase the number of infusions and the
proportion of rats that acquire nicotine self-administration
(Cohen et al., 2005). Similarly, smoking relapse in humans is
highly dependent on environmental triggers (Le Foll and Gold-
berg, 2005).
Our findings after ethanol also concur with literature reports.
Perra et al. (2005) demonstrated that rimonabant prevents and
reverses ethanol-induced increases in dopamine neuron activity.
Hungund et al. (2003) also showed that rimonabant attenuates
the increase in dopamine release obtained with microdialysis.
The modest effect of ethanol observed in those studies and in ours
may be related to the lack of a specific signal transduction
mechanism.
Whereas our results indicate that rimonabant can attenuate
cocaine-induced increases in dopamine release, Soria et al.
(2005) reported similar extracellular dopamine increases in wild-
type and CB1 receptor-deficient mice, as well as in rimonabant-
treated wild types compared with vehicle controls. However, that
study used microdialysis and thus lacked the temporal resolution
of the present results. Other factors such as species differences
(mouse vs rat) and route of administration (intraperitoneal vs
intravenous) may also account for the discrepancies. Soria et al.
(2005) also showed that either CB1 receptor ablation or rimon-
abant treatment blunt cocaine self-administration. Our results
are consistent with this observation because dopamine transients
are critical for cocaine seeking (Phillips et al., 2003), and thus
their inhibition, as shown here, would lead to deficits in the en-
coding and expression of the behavior. Furthermore, cannabi-
noid agonists promote cue-evoked reinstatement of cocaine
seeking, responses mediated by dopamine transients (Phillips et
al., 2003), and this is blocked by rimonabant (De Vries et al.,
2001).
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With such different mechanisms of action, how does CB1 re-
ceptor blockade attenuate dopamine transients elicited by all
three drugs tested? Endocannabinoids can be produced in vari-
ous brain regions (Lupica and Riegel, 2005), and cannabinoids
delivered to the NA and VTA are rewarding (Zangen et al., 2006).
Because dopaminergic terminals lack cannabinoid receptors (Lu-
pica and Riegel, 2005), CB1 receptors located on presynaptic ter-
minals in the VTA appear likely anatomical targets for the effects
of rimonabant by preventing the binding of endocannabinoids
produced from dopaminergic neurons in the VTA (the origin of
the projection to the NA). Indeed, presynaptic CB1 receptors on
GABA and glutamatergic terminals in the VTA can modulate
dopamine neuron firing (Szabo et al., 2002; Lupica and Riegel,
2005). The attenuation of drug-induced dopamine activity
shown here suggests that rimonabant antagonizes a signaling
pathway involving a preferential endocannabinoid-mediated in-
hibition of GABA release onto dopamine neurons (Szabo et al.,
2002; Riegel and Lupica, 2004). This interaction between GABA
and endocannabinoids may not only involve the actions of drugs
of abuse belonging to different pharmacological classes, but may
also encompass the properties of more natural addictions such as
overeating (Di Marzo and Matias, 2005), a pathology that is ame-
liorated by rimonabant. Thus, our findings support the useful-
ness of a single approach to the treatment of addictions to mul-
tiple drugs of abuse and possibly to natural rewards.
References
Arnold JC (2005) The role of endocannabinoid transmission in cocaine ad-
diction. Pharmacol Biochem Behav 81:396 – 406.
Budygin EA, Phillips PE, Robinson DL, Kennedy AP, Gainetdinov RR,
Wightman RM (2001) Effect of acute ethanol on striatal dopamine neu-
rotransmission in ambulatory rats. J Pharmacol Exp Ther 297:27–34.
Castane A, Berrendero F, Maldonado R (2005) The role of the cannabinoid
system in nicotine addiction. Pharmacol Biochem Behav 81:381–386.
Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM (2004) Can-
nabinoids enhance subsecond dopamine release in the nucleus accum-
bens of awake rats. J Neurosci 24:4393– 4400.
Chou IH, Narasimhan K (2005) Neurobiology of addiction. Nat Neurosci
8:1427.
Cohen C, Kodas E, Griebel G (2005) CB1 receptor antagonists for the treat-
ment of nicotine addiction. Pharmacol Biochem Behav 81:387–395.
Colombo G, Serra S, Vacca G, Carai MA, Gessa GL (2005) Endocannabi-
noid system and alcohol addiction: pharmacological studies. Pharmacol
Biochem Behav 81:369 –380.
De Vries TJ, Schoffelmeer AN (2005) Cannabinoid CB1 receptors control
conditioned drug seeking. Trends Pharmacol Sci 26:420 – 426.
De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J,
Vanderschuren LJ, Schoffelmeer AN (2001) A cannabinoid mechanism
in relapse to cocaine seeking. Nat Med 7:1151–1154.
Di Chiara G, Imperato A (1988) Drugs abused by humans preferentially
increase synaptic dopamine concentrations in the mesolimbic system of
freely moving rats. Proc Natl Acad Sci USA 85:5274 –5278.
Di Marzo V, Matias I (2005) Endocannabinoid control of food intake and
energy balance. Nat Neurosci 8:585–589.
Gardner EL (2005) Endocannabinoid signaling system and brain reward:
emphasis on dopamine. Pharmacol Biochem Behav 81:263–284.
Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu G (1985) Low doses of
ethanol activate dopaminergic neurons in the ventral tegmental area.
Brain Res 348:201–203.
Gozzi A, Schwarz A, Reese T, Bertani S, Crestan V, Bifone A (2006) Region-
specific effects of nicotine on brain activity: a pharmacological MRI study
in the drug-naive rat. Neuropsychopharmacology 31:1690 –1703.
Heien ML, Khan AS, Ariansen JL, Cheer JF, Phillips PE, Wassum KM, Wight-
man RM (2005) Real-time measurement of dopamine fluctuations after
cocaine in the brain of behaving rats. Proc Natl Acad Sci USA
102:10023–10028.
Hungund BL, Szakall I, Adam A, Basavarajappa BS, Vadasz C (2003) Can-
nabinoid CB1 receptor knockout mice exhibit markedly reduced volun-
tary alcohol consumption and lack alcohol-induced dopamine release in
the nucleus accumbens. J Neurochem 84:698 –704.
Le Foll B, Goldberg SR (2005) Control of the reinforcing effects of nicotine
by associated environmental stimuli in animals and humans. Trends
Pharmacol Sci 26:287–293.
Lupica CR, Riegel AC (2005) Endocannabinoid release from midbrain do-
pamine neurons: a potential substrate for cannabinoid receptor antago-
nist treatment of addiction. Neuropharmacology 48:1105–1116.
Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR,
Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR,
Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ,
McCallum SE, Parameswaran N, et al. (2006) Guidelines on nicotine
dose selection for in vivo research. Psychopharmacology (Berl), in press.
Nomikos GG, Damsma G, Wenkstern D, Fibiger HC (1990) In vivo charac-
terization of locally applied dopamine uptake inhibitors by striatal micro-
dialysis. Synapse 6:106 –112.
O’Brien CP, Gardner EL (2005) Critical assessment of how to study addic-
tion and its treatment: human and non-human animal models. Pharma-
col Ther 108:18 –58.
Perra S, Pillolla G, Melis M, Muntoni AL, Gessa GL, Pistis M (2005) Involve-
ment of the endogenous cannabinoid system in the effects of alcohol in
the mesolimbic reward circuit: electrophysiological evidence in vivo. Psy-
chopharmacology (Berl) 183:368 –377.
Phillips PE, Stuber GD, Heien ML, Wightman RM, Carelli RM (2003) Subsec-
ond dopamine release promotes cocaine seeking. Nature 422:614–618.
Pidoplichko VI, DeBiasi M, Williams JT, Dani JA (1997) Nicotine activates
and desensitizes midbrain dopamine neurons. Nature 390:401– 404.
Riegel AC, Lupica CR (2004) Independent presynaptic and postsynaptic
mechanisms regulate endocannabinoid signaling at multiple synapses in
the ventral tegmental area. J Neurosci 24:11070 –11078.
Robinson DL, Brunner LJ, Gonzales RA (2002a) Effect of gender and es-
trous cycle on the pharmacokinetics of ethanol in the rat brain. Alcohol
Clin Exp Res 26:165–172.
Robinson DL, Heien ML, Wightman RM (2002b) Frequency of dopamine
concentration transients increases in dorsal and ventral striatum of male
rats during introduction of conspecifics. J Neurosci 22:10477–10486.
Robinson DL, Volz TJ, Schenk JO, Wightman RM (2005) Acute ethanol
decreases dopamine transporter velocity in rat striatum: in vivo and in
vitro electrochemical measurements. Alcohol Clin Exp Res 29:746 –755.
Roitman MF, Stuber GD, Phillips PE, Wightman RM, Carelli RM (2004)
Dopamine operates as a subsecond modulator of food seeking. J Neurosci
24:1265–1271.
Schultz W, Dayan P, Montague PR (1997) A neural substrate of prediction
and reward. Science 275:1593–1599.
Soria G, Mendizabal V, Tourino C, Robledo P, Ledent C, Parmentier M,
Maldonado R, Valverde O (2005) Lack of CB1 cannabinoid receptor
impairs cocaine self-administration. Neuropsychopharmacology
30:1670 –1680.
Szabo B, Siemes S, Wallmichrath I (2002) Inhibition of GABAergic neuro-
transmission in the ventral tegmental area by cannabinoids. Eur J Neuro-
sci 15:2057–2061.
Turner TJ (2004) Nicotine enhancement of dopamine release by a calcium-
dependent increase in the size of the readily releasable pool of synaptic
vesicles. J Neurosci 24:11328 –11336.
Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA (2006) Two brain
sites for cannabinoid reward. J Neurosci 26:4901– 4907.
Cheer et al. • Cannabinoid/Dopamine Interactions J. Neurosci., January 24, 2007 • 27(4):791–795 • 795
